Psyence BioMed Invested $5M to Support Ibogaine Trials
Biotech firms in Texas are scaling pharmaceutical-grade production to prepare for upcoming clinical testing.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should pharmaceutical companies prioritize the development and manufacturing of experimental drugs for clinical research?
Psyence BioMed has committed $5 million in total cash and agreed to a value-matched share exchange with PsyLabs to advance ibogaine manufacturing. The companies are aligning resources to support a planned clinical trial in Texas.
Why it matters
The deal aims to formalize a supply chain for pharmaceutical-grade ibogaine, a critical step for operators navigating the early-stage regulatory pathway for psychedelic-based medical treatments. Aligning manufacturing and testing capabilities now is necessary for these firms to meet stringent requirements for U.S.-based clinical trials.
Psyence BioMed committed $2.4 million in initial cash to PsyLabs, with the remaining $2.6 million contingent on milestones.
The players
Psyence BioMed
A life sciences company focused on the development and production of psilocybin and other psychedelic compounds for clinical applications.
PsyLabs
A research entity currently holding a 30.22% stake in Psyence BioMed, specializing in pharmaceutical-grade manufacturing.
Texas Ibogaine Research Corporation
A subsidiary established in Texas by Psyence BioMed to manage and oversee state-level clinical trial operations.
The details
The cash investment is tied to a $54 million pre-money equity valuation of PsyLabs, with the secondary tranche of $2.6 million payable upon reaching specific development milestones. Through the share exchange, Psyence BioMed will issue 1,497,500 common shares and receive 3,473 ordinary shares, deepening the cross-ownership between the two entities. Operations will be managed through the newly established Texas Ibogaine Research Corporation, which functions as the platform for the clinical testing program.
Timeline
September 23, 2026: The investment and share exchange were announced.
November 30, 2026: Closing deadline for the share exchange agreement.
December 31, 2026: Final milestone deadline for the remaining investment tranches.
Market Landscape
This move follows a trend of firms vertically integrating manufacturing to meet FDA clinical trial investigational new drug (IND) regulatory standards. By formalizing these capabilities in Texas, the companies are positioning themselves to meet technical compliance requirements for large-scale studies.
Operators in the biotech sector should track the milestone-based funding structure as a benchmark for managing cash flow in speculative drug development. Ensure that all manufacturing partnerships have clearly defined delivery metrics tied to regulatory compliance dates.
The takeaway
This partnership highlights the importance of securing vertically integrated manufacturing before launching clinical trials in new jurisdictions. Leaders should monitor the December 31, 2026 milestone deadline to gauge the feasibility of the project's timeline.
What happens next
The share exchange agreement faces a closing deadline of November 30, 2026, while the remaining $2.6 million in investment capital must reach milestones by December 31, 2026, to avoid lapsing.
Further reading
For more on the operational hurdles facing new clinical programs, see our coverage of Healthcare.
Live Poll
Should pharmaceutical companies prioritize the development and manufacturing of experimental drugs for clinical research?
